Densitometric analysis revealed that Orkambi® treatment resulted in a significant increase of Band C in CF MNCs at 6 and 12 months and that the CFTR protein amount at 12 months was similar to that of non-CF MNCs (Figure 3C). This evidence concerns the gene CFTR and cystic fibrosis.